Profile data is unavailable for this security.
About the company
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
- Revenue in USD (TTM)149.55m
- Net income in USD12.46m
- Incorporated1990
- Employees378.00
- LocationKamada Ltd2 Holtzman St., Science ParkREHOVOT 7670402IsraelISR
- Phone+972 89406472
- Fax+972 89406473
- Websitehttps://www.kamada.com/
More ▼
14.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Phoenix Investments House Ltd.as of 31 Dec 2023 | 4.16m | 7.24% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 1.38m | 2.41% |
| Meitav Mutual Funds Ltd.as of 29 Feb 2024 | 834.42k | 1.45% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 624.77k | 1.09% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 386.97k | 0.67% |
| Analyst IMS Mutual Funds Management (1986) Ltd.as of 29 Feb 2024 | 177.64k | 0.31% |
| Excellence Nessuah Mutual Funds Management Ltd.as of 31 Dec 2023 | 154.35k | 0.27% |
| KSM Mutual Funds Ltd.as of 29 Feb 2024 | 150.09k | 0.26% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 122.38k | 0.21% |
| More Mutual Funds Management (2013) Ltd.as of 29 Feb 2024 | 102.32k | 0.18% |
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
